STAT3


Also found in: Acronyms, Wikipedia.

STAT3

A gene on chromosome 17q21.31 that encodes a member of the STAT family of transcription factors, which are phosphorylated by receptor-associated kinases in response to cytokines and growth factors, including IFNs, EGF, IL5, IL6, HGF, LIF and BMP2. The STAT3 protein product mediates expression of various genes in response to cell stimuli, and thus plays a key role in cell growth and apoptosis. GTPase Rac1 binds and upregulates STAT3; PIAS3 inhibits it.
References in periodicals archive ?
Immunological assessment of individuals with STAT3 GoF mutations identified total serum IgE below the lower reference limit of age-matched controls in all 6 cases, (<2 kU/L, range 0.
Carnosic acid inhibits STAT3 signaling and induces apoptosis through generation of ROS in human colon cancer HCTU6 cells.
Protein expression analysis reveals that TCZ up-regulates Bcl-xL, inhibits Caspase 3, and induces the activation of STAT3.
Opposing roles of STAT-1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS.
No mutations in MET, BRAF, mTOR (FRAP1), STAT3, JAK2, AKT1-3, or PTEN were detected.
Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
As a transcription factor, STAT3 has been implicated to protect hearts from acute ischemic injury under stressful conditions [93], and loss of STAT3 will result in cardiomyopathy [94].
ATBF1 interacts with protein inhibitor of activated STAT3 (PIAS3) by forming ATBF1-PIAS3 complex and combining with active STAT3, thereby inhibiting expression of proliferative genes by reducing STAT3-DNA binding activity (Nojiri et al.
The endpoints for the study include measurements of anti-tumuor activity, STAT3 protein levels in tumour biopsies and STAT3-related biomarkers.
4+] T cells and significant contribution of STAT3 to the IL-27-mediated cytokine suppression in fully activated [CD.
AST inhibited the expression of STAT3, its upstream activator JAK1, and the STAT3 target antiapoptotic genes bcl-2, bcl-xl, and c-myc.
Several inhibitors of NF-[kappa]B or STAT3 have been reported to enhance the effect of therapeutic agents in the treatment of bone metastasis in prostate cancer.